Clinical Trial Results: A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sotorasib (AMG 510) for first-line treatment in stage IV non-small cell lung cancer with KRAS p.G12C mutation; study terminated with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• sotorasib (sotorasib)

Snippet

Sponsor: Amgen | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2026-07-13